Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Q/C TECHNOLOGIES, INC. Director's Dealing 2019

May 30, 2019

35313_dirs_2019-05-30_c7562d7b-5ada-4771-91ba-c77156bfeccf.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Akers Biosciences, Inc. (AKER)
CIK: 0001321834
Period of Report: 2019-05-24

Reporting Person: Yeaton Howard (CEO, CFO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2019-05-24 Common Stock A 7500 $0.65 Acquired 30000 Direct